Pablo M. Bedano

Hematology
7229 Clearvista Dr
Indianapolis, IN 46256

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 15, 2024
Showing 1-1 of 1

Last Updated: 09/26/2026